Joe Rogan Experience #2553 - Andrew Hubermsan · Aired Sep 14, 2026
Claim summary · not a verbatim quotation
There have been clinical trials using MDMA for PTSD treatment where participants moved through their PTSD within a total of four to six weeks using two sessions spaced about a month apart.
The finding
What the evidence shows
There is a kernel here, because several earlier Phase 2 trials did use two MDMA sessions spaced about a month apart. But the trials that produced the headline PTSD results used three 8-hour MDMA sessions four weeks apart, with three preparatory and nine integration therapy sessions around them, running 18 weeks to the main measurement point, where 67 percent of the MDMA group no longer met the criteria for PTSD. Even the two-session Phase 2 design ran longer than four to six weeks once the preparation and integration sessions are counted.
Read the supporting source · maps.org ↗Quick answer & review status
Quick answer
Is it true that there have been clinical trials using MDMA for PTSD treatment where participants moved through their PTSD within a total of four to six weeks using two sessions spaced about a month apart?
Partly. The claim stretches what the evidence shows. There is a kernel here, because several earlier Phase 2 trials did use two MDMA sessions spaced about a month apart. Andrew Hubermsan said it (matched by voice) on Joe Rogan Experience #2553 - Andrew Hubermsan, aired Sep 14, 2026, at 21:46. The supporting source is maps.org, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.